AUTHOR=Wang Tao , Wang Xiao-tong , Lai Ran , Ling Hong-wei , Zhang Fan , Lu Qian , Lv Dong-mei , Yin Xiao-xing 

TITLE=MTNR1B Gene Polymorphisms Are Associated With the Therapeutic Responses to Repaglinide in Chinese Patients With Type 2 Diabetes Mellitus

JOURNAL=Frontiers in Pharmacology

VOLUME=10

YEAR=2019

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.01318

DOI=10.3389/fphar.2019.01318

ISSN=1663-9812

ABSTRACT=<p>The objective of this study was to investigate whether <italic>MTNR1B</italic> gene variants influence repaglinide response in Chinese patients with newly diagnosed type 2 diabetes mellitus (T2DM). A total of 300 patients with T2DM and 200 control subjects were enrolled to identify <italic>MTNR1B</italic> rs10830963 and rs1387153 genotypes by real-time polymerase chain reaction (PCR), with subsequent high-resolution melting (HRM) analysis. Ninety-five patients with newly diagnosed T2DM were randomly selected to undergo 8 weeks of repaglinide treatment (3 mg/day). After 8-week repaglinide monotherapy, patients with at least one G allele of <italic>MTNR1B</italic> rs10830963 showed a smaller decrease in fasting plasma glucose (FPG) (<italic>P</italic> = 0.031) and a smaller increase in homeostasis model assessment for beta cell function (HOMA-B) (<italic>P</italic> = 0.002) levels than those with the CC genotype did. The T allele carriers at rs1387153 exhibited a smaller decrease in FPG (<italic>P</italic> = 0.007) and smaller increases in postprandial serum insulin (PINS) (<italic>P</italic> = 0.016) and HOMA-B (<italic>P</italic> &lt; 0.001) levels compared to individuals with the CC genotype. These data suggest that the <italic>MTNR1B</italic> rs10830963 and rs1387153 polymorphisms are associated with repaglinide monotherapy efficacy in Chinese patients with T2DM.</p>